Recombinant Human Endothelial-Monocyte Activating Polypeptide II (rHuEMAP-II)
SCYE1, EMAP-2, Small Inducible Cytokine Subfamily E Member 1
SKPIDVSRLD LRIGCIITAR KHPDADSLYV EEVDVGEIAP RTVVSGLVNH VPLEQMQNRM VILLCNLKPA KMRGVLSQAM VMCASSPEKI EILAPPNGSV PGDRITFDAF PGEPDKELNP KKKIWEQIQP DLHTNDECVA TYKGVPFEVK GKGVCRAQTM SNSGIK
Endothelial-Monocyte Activating Polypeptide II (EMAP-II) is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues.
Approximately 18.2 kDa, a single non-glycosylated polypeptide chain containing 166 amino acids.
Fully biologically active when compared to standard. The ED50 as determined by the apoptotic effect using serum free human MCF-7 cells is less than 40 ng/ml, corresponding to a specific activity of > 2.5 × 104 IU/mg.
Sterile filtered white lyophilized (freeze-dried) powder.
Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.4.
Less than 1 EU/ug of rHuEMAP-II as determined by LAL method.
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
> 98 % by SDS-PAGE and HPLC analyses.
Recombinant Human Endothelial-Monocyte Activating Polypeptide II是ChemWhat品牌授权产品并通过沃尔森销售，下面是ChemWhat上的该产品链接 Recombinant Human Endothelial-Monocyte Activating Polypeptide II (rHuEMAP-II)